Synmosa Biopharma Corporation (4114.TWO)
TWD 33.45
(0.0%)
TWD 33.45
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 511.92 Million | 630.24 Million | 454.86 Million | 254.4 Million | -46.11 Million |
| Net Income | 601.55 Million | 725.01 Million | 153.88 Million | 497.64 Million | 47.09 Million |
| Depreciation & Amortization | 339.92 Million | 320.37 Million | 302.05 Million | 302.15 Million | 262.19 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 17.2 Million | 22.47 Million | 10.63 Million | 4.29 Million | - |
| Change in working capital | -319.98 Million | -155.71 Million | -24.26 Million | -236.12 Million | -108.78 Million |
| Other non-cash items | 55.67 Million | 59.56 Million | 49.72 Million | -141.29 Million | -246.6 Million |
| Investing Cash Flow | -717.87 Million | -69.33 Million | 73.33 Million | 34.49 Million | -395.94 Million |
| Investments in PPE | -269.76 Million | -184.32 Million | -142.12 Million | -177.2 Million | -183.37 Million |
| Acquisitions | -24.97 Million | -72.63 Million | 466 Thousand | 110.59 Million | -36.49 Million |
| Investment purchases | -783.52 Million | -659.97 Million | -22.76 Million | -40.44 Million | -169.51 Million |
| Sales/Maturities of investments | 353.52 Million | 542.95 Million | 20.77 Million | 116.79 Million | 142.22 Million |
| Other Investing Activities | -19.16 Million | 297.65 Million | 212.64 Million | 12 Million | -115.5 Million |
| Financing Cash Flow | 37.24 Million | -347.94 Million | -297.56 Million | -111.78 Million | 461.58 Million |
| Debt repayment | -939.6 Million | -159.36 Million | -241.84 Million | -43.25 Million | -761.21 Million |
| Dividends payments | -194.43 Million | -148.63 Million | -79.97 Million | -45.69 Million | -38.01 Million |
| Common Stock Repurchased | - | -108.97 Million | -51.64 Million | - | -199.97 Million |
| Common Stock Issuance | 950 Million | 40.23 Million | 612 Thousand | - | - |
| Other Financing Activities | 310.8 Million | 103.12 Million | 134.09 Million | -47.72 Million | -61.64 Million |
| Accounts receivables | -29.16 Million | - | - | - | 7.86 Million |
| Accounts payables | -8.08 Million | - | - | - | 114.3 Million |
| Inventory | -305.39 Million | -120.94 Million | 16.87 Million | -172.65 Million | -177.69 Million |
| Other working capital | 14.56 Million | - | - | - | -53.26 Million |
| Cash at beginning of period | 1.08 Billion | 868.16 Million | 638.34 Million | 465.1 Million | 452.08 Million |
| Cash at end of period | 918.55 Million | 1.08 Billion | 868.16 Million | 638.34 Million | 468.1 Million |
| Capital Expenditure | -269.76 Million | -184.32 Million | -142.12 Million | -177.2 Million | -183.37 Million |
| Effect of forex changes on cash | -389 Thousand | 6.51 Million | -808 Thousand | -3.87 Million | - |
| Net cash flow / Change in cash | -169.09 Million | 219.48 Million | 229.82 Million | 173.24 Million | 16.02 Million |
| Free Cash Flow | 242.16 Million | 445.92 Million | 312.73 Million | 77.19 Million | -229.48 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 193.71 Million | 185.31 Million | 601.55 Million | 157.82 Million | 133.15 Million | 192.81 Million |
| Depreciation & Amortization | 85.31 Million | 86.01 Million | 339.92 Million | 85.77 Million | 85.27 Million | 86.23 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.3 Million | 2.18 Million | 17.2 Million | 8.5 Million | 1.11 Million | 5.15 Million |
| Change in working capital | -23.92 Million | -127.18 Million | -319.98 Million | -49.98 Million | -134.68 Million | -42.91 Million |
| Other non-cash items | 9.48 Million | 11.97 Million | 55.67 Million | 9.69 Million | 13.46 Million | 15.57 Million |
| Investing Cash Flow | 174.25 Million | -194.04 Million | -717.87 Million | -358.32 Million | -196.5 Million | 19.59 Million |
| Investments in PPE | -57.97 Million | -105.83 Million | -269.76 Million | -68.28 Million | -63.87 Million | -43.45 Million |
| Acquisitions | 3.08 Million | 33 Thousand | -24.97 Million | 7.91 Million | 14.05 Million | -35.02 Million |
| Investment purchases | -197.68 Million | -124.51 Million | -783.52 Million | -297.9 Million | -162.53 Million | -165.84 Million |
| Sales/Maturities of investments | 411.03 Million | 33.65 Million | 353.52 Million | -1.45 Million | 23.87 Million | 260.53 Million |
| Other Investing Activities | 11.06 Million | 511 Thousand | -19.16 Million | -5.7 Million | -13.13 Million | -106 Thousand |
| Financing Cash Flow | -95.52 Million | 133.62 Million | 37.24 Million | 276.78 Million | -1.22 Billion | 930.2 Million |
| Debt repayment | -74.42 Million | -154.09 Million | -939.6 Million | -13.86 Million | -1.01 Billion | -5.31 Million |
| Dividends payments | - | - | -194.43 Million | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 950 Million | - | - | 950 Million |
| Other Financing Activities | -6.15 Million | -18 Thousand | 310.8 Million | 311.09 Million | 1000.00 | - |
| Accounts receivables | -15.31 Million | - | - | - | - | - |
| Accounts payables | 76 Million | - | - | - | - | - |
| Inventory | -49.69 Million | -411 Thousand | -305.39 Million | -55.04 Million | -44.55 Million | -157.66 Million |
| Other working capital | -32.1 Million | - | - | - | - | - |
| Cash at beginning of period | 1 Billion | 918.55 Million | 1.08 Billion | 802.38 Million | 2.18 Billion | 1.09 Billion |
| Cash at end of period | 1.23 Billion | 1 Billion | 918.55 Million | 918.55 Million | 802.38 Million | 2.18 Billion |
| Capital Expenditure | -57.97 Million | -105.83 Million | -269.76 Million | -68.28 Million | -63.87 Million | -43.45 Million |
| Effect of forex changes on cash | 2.26 Million | 5.2 Million | -389 Thousand | -6.3 Million | 4.7 Million | 2.84 Million |
| Net cash flow / Change in cash | 225.67 Million | 88.08 Million | -169.09 Million | 116.17 Million | -1.38 Billion | 1.08 Billion |
| Free Cash Flow | 86.7 Million | 37.46 Million | 242.16 Million | 135.74 Million | -24.73 Million | 92.41 Million |
TARSONS
600210
6201
ADM
NDA
WEYS